26 results on '"Fehr, Danielle'
Number of results to display per page
Search Results
2. The epithelial barrier: The gateway to allergic, autoimmune, and metabolic diseases and chronic neuropsychiatric conditions
- Author
-
Yazici, Duygu, Ogulur, Ismail, Pat, Yagiz, Babayev, Huseyn, Barletta, Elena, Ardicli, Sena, Bel imam, Manal, Huang, Mengting, Koch, Jana, Li, Manru, Maurer, Debbie, Radzikowska, Urszula, Satitsuksanoa, Pattraporn, Schneider, Stephan R., Sun, Na, Traidl, Stephan, Wallimann, Alexandra, Wawrocki, Sebastian, Zhakparov, Damir, Fehr, Danielle, Ziadlou, Reihane, Mitamura, Yasutaka, Brüggen, Marie-Charlotte, van de Veen, Willem, Sokolowska, Milena, Baerenfaller, Katja, Nadeau, Kari, Akdis, Mubeccel, and Akdis, Cezmi A.
- Published
- 2023
- Full Text
- View/download PDF
3. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration.
- Author
-
Traidl‐Hoffmann, Claudia, Afghani, Jamie, Akdis, Cezmi A., Akdis, Mübecel, Aydin, Handan, Bärenfaller, Katja, Behrendt, Heidrun, Bieber, Thomas, Bigliardi, Paul, Bigliardi‐Qi, Mei, Bonefeld, Charlotte Menné, Bösch, Stefanie, Brüggen, Marie Charlotte, Diemert, Sebastian, Duchna, Hans‐Werner, Fähndrich, Martina, Fehr, Danielle, Fellmann, Marc, Frei, Remo, and Garvey, Lena H.
- Subjects
PATIENT advocacy ,ATOPIC dermatitis ,TARGETED advertising ,DISEASE management ,STAKEHOLDER analysis - Abstract
The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient‐centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Navigating the evolving landscape of atopic dermatitis:Challenges and future opportunities: The 4th Davos declaration
- Author
-
Traidl-Hoffmann, Claudia, Afghani, Jamie, Akdis, Cezmi, Akdis, Mübecel, Aydin, Handan, Bärenfaller, Katja, Behrendt, Heidrun, Bieber, Thomas, Bigliardi, Paul, Bigliardi-Qi, Mei, Bonefeld, Charlotte Menné, Bösch, Stefanie, Brüggen, Marie Charlotte, Diemert, Sebastian, Duchna, Hans Werner, Fähndrich, Martina, Fehr, Danielle, Fellmann, Marc, Frei, Remo, Garvey, Lena H., Gharbo, Raschid, Gökkaya, Mehmet, Grando, Karin, Guillet, Carole, Guler, Erman, Gutermuth, Jan, Herrmann, Nadine, Hijnen, Dirk Jan, Hülpüsch, Claudia, Irvine, Alan D., Jensen-Jarolim, Erika, Kong, Heidi H., Koren, Hillel, Lang, Claudia C.V., Lauener, Roger, Maintz, Laura, Mantel, Pierre Yves, Maverakis, Emanuel, Möhrenschlager, Matthias, Müller, Svenja, Nadeau, Kari, Neumann, Avidan U., O'Mahony, Liam, Rabenja, Fahafahantsoa Rapelanoro, Renz, Harald, Rhyner, Claudio, Rietschel, Ernst, Ring, Johannes, Roduit, Caroline, Sasaki, Mari, Schenk, Mirjam, Schröder, Jens, Simon, Dagmar, Simon, Hans Uwe, Sokolowska, Milena, Ständer, Sonja, Steinhoff, Martin, Piccirillo, Doris Straub, Taïeb, Alain, Takaoka, Roberto, Tapparo, Martin, Teixeira, Henrique, Thyssen, Jacob Pontoppidan, Traidl, Stephan, Uhlmann, Miriam, van de Veen, Willem, van Hage, Marianne, Virchow, Christian, Wollenberg, Andreas, Yasutaka, Mitamura, Zink, Alexander, Schmid-Grendelmeier, Peter, Traidl-Hoffmann, Claudia, Afghani, Jamie, Akdis, Cezmi, Akdis, Mübecel, Aydin, Handan, Bärenfaller, Katja, Behrendt, Heidrun, Bieber, Thomas, Bigliardi, Paul, Bigliardi-Qi, Mei, Bonefeld, Charlotte Menné, Bösch, Stefanie, Brüggen, Marie Charlotte, Diemert, Sebastian, Duchna, Hans Werner, Fähndrich, Martina, Fehr, Danielle, Fellmann, Marc, Frei, Remo, Garvey, Lena H., Gharbo, Raschid, Gökkaya, Mehmet, Grando, Karin, Guillet, Carole, Guler, Erman, Gutermuth, Jan, Herrmann, Nadine, Hijnen, Dirk Jan, Hülpüsch, Claudia, Irvine, Alan D., Jensen-Jarolim, Erika, Kong, Heidi H., Koren, Hillel, Lang, Claudia C.V., Lauener, Roger, Maintz, Laura, Mantel, Pierre Yves, Maverakis, Emanuel, Möhrenschlager, Matthias, Müller, Svenja, Nadeau, Kari, Neumann, Avidan U., O'Mahony, Liam, Rabenja, Fahafahantsoa Rapelanoro, Renz, Harald, Rhyner, Claudio, Rietschel, Ernst, Ring, Johannes, Roduit, Caroline, Sasaki, Mari, Schenk, Mirjam, Schröder, Jens, Simon, Dagmar, Simon, Hans Uwe, Sokolowska, Milena, Ständer, Sonja, Steinhoff, Martin, Piccirillo, Doris Straub, Taïeb, Alain, Takaoka, Roberto, Tapparo, Martin, Teixeira, Henrique, Thyssen, Jacob Pontoppidan, Traidl, Stephan, Uhlmann, Miriam, van de Veen, Willem, van Hage, Marianne, Virchow, Christian, Wollenberg, Andreas, Yasutaka, Mitamura, Zink, Alexander, and Schmid-Grendelmeier, Peter
- Abstract
The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.
- Published
- 2024
5. Sensitizations to pollen differ between Central European and Sub-Saharan African atopic dermatitis patients
- Author
-
Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Rentschler, Muriel, Sendrasoa, Fandresena; https://orcid.org/0000-0003-2606-3539, Li, Nick, White, Anna, Distler, Meike, Lang, Claudia; https://orcid.org/0000-0003-0469-7661, Masenga, Gloria, Mosha, Nelson, Semango, George, Clemens, Clara, Rasamoelina, Tahinamandranto, Soankasina, Abel Hermann, Rapelanoro Rabenja, Fahafahantsoa, Mavura, Daudi, Masenga, John Elisante, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Brüggen, Marie-Charlotte; https://orcid.org/0000-0002-8607-6254, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Rentschler, Muriel, Sendrasoa, Fandresena; https://orcid.org/0000-0003-2606-3539, Li, Nick, White, Anna, Distler, Meike, Lang, Claudia; https://orcid.org/0000-0003-0469-7661, Masenga, Gloria, Mosha, Nelson, Semango, George, Clemens, Clara, Rasamoelina, Tahinamandranto, Soankasina, Abel Hermann, Rapelanoro Rabenja, Fahafahantsoa, Mavura, Daudi, Masenga, John Elisante, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, and Brüggen, Marie-Charlotte; https://orcid.org/0000-0002-8607-6254
- Abstract
Summary Background Atopic dermatitis (AD) is often associated with allergic comorbidities, such as allergic asthma or allergic rhinoconjunctivitis (ARC). Sensitizations to pollen can directly impact AD, as patients can experience exacerbation during pollen season. This study aims to gain more insights into the pollen sensitization patterns of AD patients in Central Europe compared with sub-Saharan Africa (SSA). Methods We performed a case–control study involving a total of 90 participants: 20 AD patients and 10 healthy controls (HC) each from Switzerland (CH), Tanzania (TZ), and Madagascar (MD). We collected clinical data and serum samples and performed a multiplex IgE test (ALEX$^{2}$ Allergy Explorer, MacroArray Diagnostics, Vienna, Austria). Results The prevalence of ARC and asthma in AD patients was similar in all countries (ARC: 60% TZ, 70% CH, 75% MD; asthma: 25% TZ, 30% CH, 20% MD). Total IgE levels were significantly higher in both SSA HC populations compared with the Swiss HC. The analysis of specific IgE levels revealed major differences in sensitization patterns between Africa and Europe, especially regarding grass pollen allergens. Swiss AD patients were sensitized to various grass pollen such as Bahia grass, Bermuda grass, common reed, perennial ryegrass, rye, and timothy grass. However, these allergens were irrelevant in the SSA population: no AD patient or HC subject was sensitized to the tested grass pollen. Conclusion The considerably different sensitization patterns between European and SSA AD patients warrant the development of allergy testing and desensitization therapies tailored to the African setting. Therefore, there is a need to characterize local pollen types and counts.
- Published
- 2024
6. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration
- Author
-
Traidl‐Hoffmann, Claudia; https://orcid.org/0000-0001-5085-5179, Afghani, Jamie, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, Akdis, Mübecel; https://orcid.org/0000-0003-0554-9943, Aydin, Handan, Bärenfaller, Katja; https://orcid.org/0000-0002-1904-9440, Behrendt, Heidrun, Bieber, Thomas; https://orcid.org/0000-0002-8800-3817, Bigliardi, Paul, Bigliardi‐Qi, Mei, Bonefeld, Charlotte Menné; https://orcid.org/0000-0002-0523-6229, Bösch, Stefanie, Brüggen, Marie Charlotte; https://orcid.org/0000-0002-8607-6254, Diemert, Sebastian, Duchna, Hans‐Werner, Fähndrich, Martina, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Fellmann, Marc; https://orcid.org/0000-0003-0064-698X, Frei, Remo, Garvey, Lena H; https://orcid.org/0000-0002-7777-4501, Gharbo, Raschid, Gökkaya, Mehmet, Grando, Karin, Guillet, Carole; https://orcid.org/0000-0003-3809-0526, Guler, Erman, Gutermuth, Jan; https://orcid.org/0000-0002-5805-3784, Lang, Claudia C V; https://orcid.org/0000-0003-0469-7661, van de Veen, Willem; https://orcid.org/0000-0001-9951-6688, Yasutaka, Mitamura, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, et al, Traidl‐Hoffmann, Claudia; https://orcid.org/0000-0001-5085-5179, Afghani, Jamie, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, Akdis, Mübecel; https://orcid.org/0000-0003-0554-9943, Aydin, Handan, Bärenfaller, Katja; https://orcid.org/0000-0002-1904-9440, Behrendt, Heidrun, Bieber, Thomas; https://orcid.org/0000-0002-8800-3817, Bigliardi, Paul, Bigliardi‐Qi, Mei, Bonefeld, Charlotte Menné; https://orcid.org/0000-0002-0523-6229, Bösch, Stefanie, Brüggen, Marie Charlotte; https://orcid.org/0000-0002-8607-6254, Diemert, Sebastian, Duchna, Hans‐Werner, Fähndrich, Martina, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Fellmann, Marc; https://orcid.org/0000-0003-0064-698X, Frei, Remo, Garvey, Lena H; https://orcid.org/0000-0002-7777-4501, Gharbo, Raschid, Gökkaya, Mehmet, Grando, Karin, Guillet, Carole; https://orcid.org/0000-0003-3809-0526, Guler, Erman, Gutermuth, Jan; https://orcid.org/0000-0002-5805-3784, Lang, Claudia C V; https://orcid.org/0000-0003-0469-7661, van de Veen, Willem; https://orcid.org/0000-0001-9951-6688, Yasutaka, Mitamura, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, and et al
- Abstract
The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient‐centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.
- Published
- 2024
7. Navigating the Evolving Landscape of Atopic Dermatitis: Challenges and Future Opportunities: the 4 th Davos Declaration
- Author
-
Traidl-Hoffmann, Claudia, primary, Afghani, Jamie, additional, Akdis, Cezmi, additional, Akdis, Mubeccel, additional, Handan, Aydin, additional, Baerenfaller, Katja, additional, Behrendt, Heidrun, additional, Bieber, Thomas, additional, Bigliardi, Paul L., additional, Bigliardi-Qi, Mei, additional, Bonefeld, Charlotte, additional, Bösch, Stefanie, additional, Brüggen, Marie-Charlotte, additional, Diemert, Sebastian, additional, Duchna, Hans-Werner, additional, Fähndrich, Martina, additional, Fehr, Danielle, additional, Fellmann, Marc, additional, Frei, Remo, additional, Garvey, Lene, additional, Gharbo, Raschid, additional, Gökkaya, Mehmet, additional, Grando, Karin, additional, Guillet, Carole, additional, Güler, Erman, additional, Gutermuth, Jan, additional, Herrmann, Nadine, additional, Hijnen, DirkJan, additional, Hülpüsch, Claudia, additional, Irvine, Alan, additional, Jensen-Jarolim, Erika, additional, Kong, Heidi H, additional, Koren, Hillel, additional, Lang, Claudia, additional, Lauener, Roger, additional, Maintz, Laura, additional, Mantel, Pierre-Yves, additional, maverakis, Emanual, additional, Moehrenschlager, Matthias, additional, Müller, Svenja, additional, Nadeau, Kari, additional, Neumann, Avidan U., additional, O'Mahony, Liam, additional, Rabenja, Fahafahantsoa Rapelanoro, additional, Renz, Harald, additional, Rhyner, Claudio, additional, Rietschel, Ernst, additional, Ring, Johannes, additional, Roduit, Caroline, additional, Sasaki, Mari, additional, Schenk, Mirjam, additional, Schroder, Jens, additional, Simon, Dagmar, additional, Simon, Hans-Uwe, additional, Sokolowska, Milena, additional, stander, sonja, additional, Steinhoff, Martin, additional, Piccirillo, Doris Straub, additional, Taïeb, Alain, additional, Takaoka, Roberto, additional, Tapparo, Martin, additional, Teixeira, Henrique, additional, Thyssen, Jacob, additional, Traidl, Stephan, additional, Uhlmann, Miriam, additional, Veen, Willem van de, additional, Hage, Marianne van, additional, Virchow, Christian, additional, Wollenberg, Andreas, additional, mitamura, yasutaka, additional, Zink, Alexander, additional, and Schmid-Grendelmeier, Peter, additional
- Published
- 2024
- Full Text
- View/download PDF
8. Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients
- Author
-
Danielle Fehr, Sara Micaletto, Thomas Moehr, and Peter Schmid-Grendelmeier
- Subjects
Allergy ,Bees ,Hymenoptera venom ,Risk factors ,Wasps ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Hymenoptera stings are a major cause of anaphylaxis. Various risk factors are discussed in literature. This study aims to investigate potential risk factors for severe sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients and analyses the correlation between diagnostic test results and the severity of the allergic reaction. Methods 480 patients suffering from wasp or honeybee venom allergy were included in this retrospective case series. Only individuals allergic to Vespula spp. but not to other vespids such as Polistes were considered. The severity of their systemic field sting reaction was analysed with regard to the amount of specific IgE antibodies to whole venom extracts and to major allergens of honeybee and/or wasp venom. Furthermore, the following potential risk factors for severe sting reactions were examined: age, sex, latency time, skin symptoms, baseline serum tryptase levels and the concentration of venom inducing a positive intracutaneous test. Results The two following indicators for severe systemic sting reactions in honeybee and wasp venom allergic patients have been identified: a short latency time and the absence of skin symptoms. The patient’s age and baseline serum tryptase levels have been found to positively correlate with the grade of the sting reaction only in individuals allergic to wasp venom. No correlation could be found between the degree of sensitisation and the severity of the allergic reaction. Neither the amount of specific IgE antibodies to whole venom extracts nor to major allergens were significantly associated with the severity of the sting reaction. Conclusion The clinical history is essential for the allergological workup and therapeutic decision on Hymenoptera venom allergies. A short latency time and the absence of skin symptoms are indicators for severe systemic sting reactions, followed by the patient’s age and baseline serum tryptase levels.
- Published
- 2019
- Full Text
- View/download PDF
9. Atopic dermatitis: The importance of future research in Africa
- Author
-
Danielle Fehr, Claudia Lang, John Masenga, Daudi Mavura, Peter Schmid‐Grendelmeier, Marie‐Charlotte Brüggen, University of Zurich, Fehr, Danielle, and Brüggen, Marie-Charlotte
- Subjects
2403 Immunology ,Immunology ,2723 Immunology and Allergy ,10177 Dermatology Clinic ,Immunology and Allergy ,610 Medicine & health - Published
- 2023
10. The epithelial barrier: The gateway to allergic, autoimmune, and metabolic diseases and chronic neuropsychiatric conditions
- Author
-
Yazici, Duygu; https://orcid.org/0000-0001-9094-6542, Ogulur, Ismail; https://orcid.org/0000-0001-8282-7762, Pat, Yagiz; https://orcid.org/0000-0003-4268-4933, Babayev, Huseyn, Barletta, Elena; https://orcid.org/0000-0002-8431-4140, Ardicli, Sena, Bel imam, Manal, Huang, Mengting, Koch, Jana; https://orcid.org/0000-0002-7552-6088, Li, Manru, Maurer, Debbie; https://orcid.org/0000-0002-8543-1998, Radzikowska, Urszula; https://orcid.org/0000-0002-7341-9764, Satitsuksanoa, Pattraporn; https://orcid.org/0000-0001-9540-7759, Schneider, Stephan R, Sun, Na, Traidl, Stephan; https://orcid.org/0000-0003-4806-599X, Wallimann, Alexandra; https://orcid.org/0000-0001-6755-3679, Wawrocki, Sebastian; https://orcid.org/0000-0002-1834-4739, Zhakparov, Damir; https://orcid.org/0000-0001-7175-0843, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Ziadlou, Reihane; https://orcid.org/0000-0001-7016-6725, Mitamura, Yasutaka; https://orcid.org/0000-0001-6389-9285, Brüggen, Marie-Charlotte; https://orcid.org/0000-0002-8607-6254, van de Veen, Willem; https://orcid.org/0000-0001-9951-6688, Sokolowska, Milena; https://orcid.org/0000-0001-9710-6685, Baerenfaller, Katja; https://orcid.org/0000-0002-1904-9440, Nadeau, Kari, Akdis, Mübeccel; https://orcid.org/0000-0003-0554-9943, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, Yazici, Duygu; https://orcid.org/0000-0001-9094-6542, Ogulur, Ismail; https://orcid.org/0000-0001-8282-7762, Pat, Yagiz; https://orcid.org/0000-0003-4268-4933, Babayev, Huseyn, Barletta, Elena; https://orcid.org/0000-0002-8431-4140, Ardicli, Sena, Bel imam, Manal, Huang, Mengting, Koch, Jana; https://orcid.org/0000-0002-7552-6088, Li, Manru, Maurer, Debbie; https://orcid.org/0000-0002-8543-1998, Radzikowska, Urszula; https://orcid.org/0000-0002-7341-9764, Satitsuksanoa, Pattraporn; https://orcid.org/0000-0001-9540-7759, Schneider, Stephan R, Sun, Na, Traidl, Stephan; https://orcid.org/0000-0003-4806-599X, Wallimann, Alexandra; https://orcid.org/0000-0001-6755-3679, Wawrocki, Sebastian; https://orcid.org/0000-0002-1834-4739, Zhakparov, Damir; https://orcid.org/0000-0001-7175-0843, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Ziadlou, Reihane; https://orcid.org/0000-0001-7016-6725, Mitamura, Yasutaka; https://orcid.org/0000-0001-6389-9285, Brüggen, Marie-Charlotte; https://orcid.org/0000-0002-8607-6254, van de Veen, Willem; https://orcid.org/0000-0001-9951-6688, Sokolowska, Milena; https://orcid.org/0000-0001-9710-6685, Baerenfaller, Katja; https://orcid.org/0000-0002-1904-9440, Nadeau, Kari, Akdis, Mübeccel; https://orcid.org/0000-0003-0554-9943, and Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X
- Abstract
Since the 1960 s, our health has been compromised by exposure to over 350,000 newly introduced toxic substances, contributing to the current pandemic in allergic, autoimmune and metabolic diseases. The "Epithelial Barrier Theory" postulates that these diseases are exacerbated by persistent periepithelial inflammation (epithelitis) triggered by exposure to a wide range of epithelial barrier-damaging substances as well as genetic susceptibility. The epithelial barrier serves as the body's primary physical, chemical, and immunological barrier against external stimuli. A leaky epithelial barrier facilitates the translocation of the microbiome from the surface of the afflicted tissues to interepithelial and even deeper subepithelial locations. In turn, opportunistic bacterial colonization, microbiota dysbiosis, local inflammation and impaired tissue regeneration and remodelling follow. Migration of inflammatory cells to susceptible tissues contributes to damage and inflammation, initiating and aggravating many chronic inflammatory diseases. The objective of this review is to highlight and evaluate recent studies on epithelial physiology and its role in the pathogenesis of chronic diseases in light of the epithelial barrier theory.
- Published
- 2023
11. Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood
- Author
-
Maintz, Laura; https://orcid.org/0000-0001-6053-1530, Schmitz, Marie‐Therese; https://orcid.org/0000-0003-2940-647X, Herrmann, Nadine; https://orcid.org/0000-0003-4924-2281, Müller, Svenja; https://orcid.org/0000-0002-2118-959X, Havenith, Regina; https://orcid.org/0000-0003-0148-7159, Brauer, Juliette; https://orcid.org/0000-0001-6975-2559, Rhyner, Claudio; https://orcid.org/0000-0003-3339-3923, Dreher, Anita; https://orcid.org/0000-0001-8823-6621, Bersuch, Eugen; https://orcid.org/0000-0003-1409-1786, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Hammel, Gertrud; https://orcid.org/0000-0002-1800-7679, Reiger, Matthias; https://orcid.org/0000-0002-6173-2104, Luschkova, Daria; https://orcid.org/0000-0003-3354-4277, Neumann, Avidan; https://orcid.org/0000-0002-2149-5917, Lang, Claudia C V; https://orcid.org/0000-0003-0469-7661, Renner, Ellen D; https://orcid.org/0000-0001-9816-8538, Schmid‐Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Traidl‐Hoffmann, Claudia; https://orcid.org/0000-0001-5085-5179, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, Lauener, Roger; https://orcid.org/0000-0002-8412-606X, Brüggen, Marie‐Charlotte; https://orcid.org/0000-0002-8607-6254, Schmid, Matthias; https://orcid.org/0000-0002-0788-0317, Bieber, Thomas; https://orcid.org/0000-0002-8800-3817, Maintz, Laura; https://orcid.org/0000-0001-6053-1530, Schmitz, Marie‐Therese; https://orcid.org/0000-0003-2940-647X, Herrmann, Nadine; https://orcid.org/0000-0003-4924-2281, Müller, Svenja; https://orcid.org/0000-0002-2118-959X, Havenith, Regina; https://orcid.org/0000-0003-0148-7159, Brauer, Juliette; https://orcid.org/0000-0001-6975-2559, Rhyner, Claudio; https://orcid.org/0000-0003-3339-3923, Dreher, Anita; https://orcid.org/0000-0001-8823-6621, Bersuch, Eugen; https://orcid.org/0000-0003-1409-1786, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Hammel, Gertrud; https://orcid.org/0000-0002-1800-7679, Reiger, Matthias; https://orcid.org/0000-0002-6173-2104, Luschkova, Daria; https://orcid.org/0000-0003-3354-4277, Neumann, Avidan; https://orcid.org/0000-0002-2149-5917, Lang, Claudia C V; https://orcid.org/0000-0003-0469-7661, Renner, Ellen D; https://orcid.org/0000-0001-9816-8538, Schmid‐Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Traidl‐Hoffmann, Claudia; https://orcid.org/0000-0001-5085-5179, Akdis, Cezmi A; https://orcid.org/0000-0001-8020-019X, Lauener, Roger; https://orcid.org/0000-0002-8412-606X, Brüggen, Marie‐Charlotte; https://orcid.org/0000-0002-8607-6254, Schmid, Matthias; https://orcid.org/0000-0002-0788-0317, and Bieber, Thomas; https://orcid.org/0000-0002-8800-3817
- Abstract
Background: Atopic dermatitis (AD) has long been regarded as a primarily pediatric disease. However, there is growing evidence for a high rate of adult-onset AD. We aimed to characterize factors associated with adult-onset versus childhood-onset AD and controls. Methods: We analyzed cross-sectional data of the CK-CARE-ProRaD cohorts Bonn, Augsburg, Davos, Zürich of 736 adult patients stratified by age of AD onset (childhood-onset <18 years: 76.4% (subsets: 0 to 2; ≥2 to 6; ≥7 to 11; ≥12 to 18); adult-onset ≥18 years: 23.6% (subsets: ≥18 to 40; ≥41 to 60; ≥61) and 167 controls (91 atopic, 76 non-atopic)). Results: We identified active smoking to be associated with adult-onset AD versus controls (adjusted Odds Ratio (aOR) = 5.54 [95% Confidence Interval: 1.06-29.01] vs. controls$^{non-atopic}$ , aOR = 4.03 [1.20-13.45] vs. controls$^{atopic}$ ). Conjunctivitis showed a negative association versus controls$^{atopic}$ (aOR = 0.36 [0.14-0.91]). Food allergy (aOR = 2.93 [1.44-5.96]), maternal food allergy (aOR = 9.43 [1.10-80.95]), palmar hyperlinearity (aOR = 2.11 [1.05-4.25]), and academic background (aOR = 2.14 [1.00-4.54]) increased the odds of childhood-onset AD versus controls$^{atopic}$. Shared AD-associated factors were maternal AD (4-34x), increased IgE (2-20x), atopic stigmata (2-3x) with varying effect sizes depending on AD onset and control group. Patients with adult-compared to childhood-onset had doubled odds of allergic rhinitis (aOR = 2.15 [1.12-4.13]), but reduced odds to feature multiple (3-4) atopic comorbidities (aOR = 0.34 [0.14-0.84]). Adult-onset AD, particularly onset ≥61 years, grouped mainly in clusters with low contributions of personal and familial atopy and high frequencies of physical inactivity, childhood-onset AD, particularly infant-onset, mainly in "high-atopic"-clusters. Conclusions: The identified associated factors suggest partly varying endo- and exogeneous mechanisms underlying adult-onset versus childhood-onset AD. Our findings migh
- Published
- 2023
12. Predicting Dupilumab Treatment Outcome in Patients with Primary diffuse Type 2 Chronic Rhinosinusitis
- Author
-
Soyka, Michael B; https://orcid.org/0000-0003-4179-4989, Ryser, Fabio S, Brühlmann, Catrin, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Dülgeroglu, Jacqueline, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Brüggen, Marie-Charlotte; https://orcid.org/0000-0002-8607-6254, Steiner, Urs Christian; https://orcid.org/0000-0002-3905-2508, Soyka, Michael B; https://orcid.org/0000-0003-4179-4989, Ryser, Fabio S, Brühlmann, Catrin, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Dülgeroglu, Jacqueline, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Brüggen, Marie-Charlotte; https://orcid.org/0000-0002-8607-6254, and Steiner, Urs Christian; https://orcid.org/0000-0002-3905-2508
- Abstract
Background: Chronic rhinosinusitis with a type 2 inflammatory pattern (T2CRS) is believed to be restricted to the nose & sinuses and associated with polyps, without clear serologic markers. Dupilumab is a promising new therapy in difficult to treat T2CRS. No factors are known to predict dupilumab treatment outcome. Methods: Patients undergoing dupilumab treatment were assessed clinically to report ultra-short- and short-term outcome up to 90 days. Serum samples were taken on day 0 and 30 days of treatment, and proteomic analyses were performed using Olink®. The results were compared to healthy controls (HC). The aim was to identify clinical and serological markers associated with a treatment response to dupilumab. Confirmation of predictive parameters was evaluated in a prospective cohort of 20 T2CRS patients. Results: 30 patients were included, 80% of which were treatment responders. SinoNasalOutcomeTest-20 (SNOT-20) scores and the total nasal polyp score improved significantly (p<0.05) on day 7. An improvement of 2.5 points at the first visit was associated with a favorable outcome with a sensitivity of 86%. Proteomic analyses revealed significant changes compared to HC. Furthermore, we could identify OPG in the serum of dupilumab treated patients that may serve as a predictor of the clinical outcome of dupilumab treatment. The predictive value of OPG was confirmed in the second cohort. Conclusion: Clinical response after one week of treatment with dupilumab is highly associated with a favorable outcome. High sensitivity proteomic analyses can identify T2CRS specific dysregulated proteins in serum. Serum OPG may serve as a predictor for dupilumab treatment outcome before the initiation of any therapy. Keywords: Anti IL-4/13; CRS; eosinophilia; predictor; proteomics
- Published
- 2023
13. Atopic dermatitis: factors associated with age of onset in adulthood versus childhood [Abstract]
- Author
-
Maintz, Laura, Schmitz, Marie-Therese, Herrmann, Nadine, Welchowski, Thomas, Müller, Svenja, Havenith, Regina, Brauer, Juliette, Rhyner, Claudio, Dreher, Anita, Bersuch, Eugen, Fehr, Danielle, Hammel, Gertrud, Reiger, Matthias, Luschkova, Daria, Lang, Claudia, Renner, Ellen D., Schmid-Grendelmeier, Peter, Traidl-Hoffmann, Claudia, Akdis, Cezmi A., Lauener, Roger, Brüggen, Marie-Charlotte, Schmid, Matthias, and Bieber, Thomas
- Subjects
ddc:610 - Published
- 2023
14. Predicting Dupilumab Treatment Outcome in Patients with Primary diffuse Type 2 Chronic Rhinosinusitis
- Author
-
Soyka, Michael B, Ryser, Fabio S, Brühlmann, Catrin, Fehr, Danielle, Dülgeroglu, Jacqueline, Schmid-Grendelmeier, Peter, Brüggen, Marie-Charlotte, Steiner, Urs Christian, University of Zurich, and Soyka, Michael B
- Subjects
2403 Immunology ,Immunology ,10033 Clinic for Immunology ,2723 Immunology and Allergy ,Immunology and Allergy ,610 Medicine & health ,10045 Clinic for Otorhinolaryngology - Abstract
Chronic rhinosinusitis with a type 2 inflammatory pattern (T2CRS) is believed to be restricted to the nose and sinuses and associated with polyps, without clear serologic markers. Dupilumab is a promising new therapy in difficult to treat T2CRS. No factors are known to predict dupilumab treatment outcome.Patients undergoing dupilumab treatment were assessed clinically to report ultra-short- and short-term outcome up to 90 days. Serum samples were taken on day 0 and 30 days of treatment, and proteomic analyses were performed using Olink®. The results were compared with healthy controls (HC). The aim was to identify clinical and serological markers associated with a treatment response to dupilumab. Confirmation of predictive parameters was evaluated in a prospective cohort of 20 T2CRS patients.Thirty patients were included, 80% of which were treatment responders. SinoNasalOutcomeTest-20 (SNOT-20) scores and the total nasal polyp score improved significantly (p .05) on Day 7. An improvement of 2.5 points at the first visit was associated with a favorable outcome with a sensitivity of 86%. Proteomic analyses revealed significant changes compared with HC. Furthermore, we could identify OPG in the serum of dupilumab-treated patients that may serve as a predictor of the clinical outcome of dupilumab treatment. The predictive value of OPG was confirmed in the second cohort.Clinical response after 1 week of treatment with dupilumab is highly associated with a favorable outcome. High sensitivity proteomic analyses can identify T2CRS-specific dysregulated proteins in serum. Serum OPG may serve as a predictor for dupilumab treatment outcome before the initiation of any therapy.
- Published
- 2023
- Full Text
- View/download PDF
15. Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood
- Author
-
Maintz, Laura, Schmitz, Marie‐Therese, Herrmann, Nadine, Müller, Svenja, Havenith, Regina, Brauer, Juliette, Rhyner, Claudio, Dreher, Anita, Bersuch, Eugen, Fehr, Danielle, Hammel, Gertrud, Reiger, Matthias, Luschkova, Daria, Neumann, Avidan, Lang, Claudia C V, Renner, Ellen D, Schmid‐Grendelmeier, Peter, Traidl‐Hoffmann, Claudia, Akdis, Cezmi A, Lauener, Roger, Brüggen, Marie‐Charlotte, Schmid, Matthias, Bieber, Thomas, University of Zurich, and Maintz, Laura
- Subjects
2403 Immunology ,Immunology ,2723 Immunology and Allergy ,10177 Dermatology Clinic ,Immunology and Allergy ,610 Medicine & health - Published
- 2023
- Full Text
- View/download PDF
16. Atopic dermatitis: correlation of distinct risk factors with age of onset in adulthood compared to childhood
- Author
-
Maintz, Laura, primary, Schmitz, Marie‐Therese, additional, Herrmann, Nadine, additional, Müller, Svenja, additional, Havenith, Regina, additional, Brauer, Juliette, additional, Rhyner, Claudio, additional, Dreher, Anita, additional, Bersuch, Eugen, additional, Fehr, Danielle, additional, Hammel, Gertrud, additional, Reiger, Matthias, additional, Luschkova, Daria, additional, Neumann, Avidan, additional, Lang, Claudia C. V., additional, Renner, Ellen D., additional, Schmid‐Grendelmeier, Peter, additional, Traidl‐Hoffmann, Claudia, additional, Akdis, Cezmi A., additional, Lauener, Roger, additional, Brüggen, Marie‐Charlotte, additional, Schmid, Matthias, additional, and Bieber, Thomas, additional
- Published
- 2023
- Full Text
- View/download PDF
17. Atopic dermatitis: The importance of future research in Africa
- Author
-
Fehr, Danielle, primary, Lang, Claudia, additional, Masenga, John, additional, Mavura, Daudi, additional, Schmid‐Grendelmeier, Peter, additional, and Brüggen, Marie‐Charlotte, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis
- Author
-
Soyka, Michael B., primary, Ryser, Fabio S., additional, Brühlmann, Catrin, additional, Fehr, Danielle, additional, Dülgeroglu, Jacqueline, additional, Schmid‐Grendelmeier, Peter, additional, Brüggen, Marie‐Charlotte, additional, and Steiner, Urs C., additional
- Published
- 2022
- Full Text
- View/download PDF
19. Biomarkers in atopic dermatitis and psoriasis - a Delphi‐based guide through the jungle?
- Author
-
Fehr, Danielle, Brüggen, Marie-Charlotte, and University of Zurich
- Subjects
2708 Dermatology ,Infectious Diseases ,10177 Dermatology Clinic ,610 Medicine & health ,2725 Infectious Diseases ,Dermatology - Published
- 2022
20. Biomarkers in atopic dermatitis and psoriasis-a Delphi-based guide through the jungle?
- Author
-
Danielle Fehr and Marie-Charlotte Brüggen
- Subjects
Infectious Diseases ,Humans ,Psoriasis ,Dermatology ,Biomarkers ,Dermatitis, Atopic - Published
- 2022
21. Faculty Opinions recommendation of An open microfluidic coculture model of fibroblasts and eosinophils to investigate mechanisms of airway inflammation.
- Author
-
Brüggen, Marie-Charlotte, primary, Ziadlou, Reihane, additional, and Fehr, Danielle, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Biomarkers in atopic dermatitis and psoriasis - a Delphi‐based guide through the jungle?
- Author
-
Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, Brüggen, Marie-Charlotte; https://orcid.org/0000-0002-8607-6254, Fehr, Danielle; https://orcid.org/0000-0001-6361-3662, and Brüggen, Marie-Charlotte; https://orcid.org/0000-0002-8607-6254
- Published
- 2022
23. Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis.
- Author
-
Soyka, Michael B., Ryser, Fabio S., Brühlmann, Catrin, Fehr, Danielle, Dülgeroglu, Jacqueline, Schmid‐Grendelmeier, Peter, Brüggen, Marie‐Charlotte, and Steiner, Urs C.
- Subjects
DUPILUMAB ,TREATMENT effectiveness ,NASAL polyps ,NASAL tumors ,SINUSITIS ,BLOOD proteins ,BIOMARKERS - Abstract
Background: Chronic rhinosinusitis with a type 2 inflammatory pattern (T2CRS) is believed to be restricted to the nose and sinuses and associated with polyps, without clear serologic markers. Dupilumab is a promising new therapy in difficult to treat T2CRS. No factors are known to predict dupilumab treatment outcome. Methods: Patients undergoing dupilumab treatment were assessed clinically to report ultra‐short‐ and short‐term outcome up to 90 days. Serum samples were taken on day 0 and 30 days of treatment, and proteomic analyses were performed using Olink®. The results were compared with healthy controls (HC). The aim was to identify clinical and serological markers associated with a treatment response to dupilumab. Confirmation of predictive parameters was evaluated in a prospective cohort of 20 T2CRS patients. Results: Thirty patients were included, 80% of which were treatment responders. SinoNasalOutcomeTest‐20 (SNOT‐20) scores and the total nasal polyp score improved significantly (p <.05) on Day 7. An improvement of 2.5 points at the first visit was associated with a favorable outcome with a sensitivity of 86%. Proteomic analyses revealed significant changes compared with HC. Furthermore, we could identify OPG in the serum of dupilumab‐treated patients that may serve as a predictor of the clinical outcome of dupilumab treatment. The predictive value of OPG was confirmed in the second cohort. Conclusion: Clinical response after 1 week of treatment with dupilumab is highly associated with a favorable outcome. High sensitivity proteomic analyses can identify T2CRS‐specific dysregulated proteins in serum. Serum OPG may serve as a predictor for dupilumab treatment outcome before the initiation of any therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients
- Author
-
Fehr, Danielle, primary, Micaletto, Sara, additional, Moehr, Thomas, additional, and Schmid-Grendelmeier, Peter, additional
- Published
- 2019
- Full Text
- View/download PDF
25. Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients
- Author
-
Fehr, Danielle, Micaletto, Sara, Moehr, Thomas, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Fehr, Danielle, Micaletto, Sara, Moehr, Thomas, and Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370
- Abstract
Background Hymenoptera stings are a major cause of anaphylaxis. Various risk factors are discussed in literature. This study aims to investigate potential risk factors for severe sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients and analyses the correlation between diagnostic test results and the severity of the allergic reaction. Methods 480 patients suffering from wasp or honeybee venom allergy were included in this retrospective case series. Only individuals allergic to Vespula spp. but not to other vespids such as Polistes were considered. The severity of their systemic field sting reaction was analysed with regard to the amount of specific IgE antibodies to whole venom extracts and to major allergens of honeybee and/or wasp venom. Furthermore, the following potential risk factors for severe sting reactions were examined: age, sex, latency time, skin symptoms, baseline serum tryptase levels and the concentration of venom inducing a positive intracutaneous test. Results The two following indicators for severe systemic sting reactions in honeybee and wasp venom allergic patients have been identified: a short latency time and the absence of skin symptoms. The patient’s age and baseline serum tryptase levels have been found to positively correlate with the grade of the sting reaction only in individuals allergic to wasp venom. No correlation could be found between the degree of sensitisation and the severity of the allergic reaction. Neither the amount of specific IgE antibodies to whole venom extracts nor to major allergens were significantly associated with the severity of the sting reaction. Conclusion The clinical history is essential for the allergological workup and therapeutic decision on Hymenoptera venom allergies. A short latency time and the absence of skin symptoms are indicators for severe systemic sting reactions, followed by the patient’s age and baseline serum tryptase levels.
- Published
- 2019
26. Atopic dermatitis: The importance of future research in Africa.
- Author
-
Fehr, Danielle, Lang, Claudia, Masenga, John, Mavura, Daudi, Schmid‐Grendelmeier, Peter, and Brüggen, Marie‐Charlotte
- Subjects
- *
ATOPIC dermatitis , *ENVIRONMENTAL impact analysis , *ATOPY - Abstract
Evidence for different immune signatures and sensitization patterns in sub-Saharan African vs. central European atopic dermatitis patients. In our work, however, we identified higher serum levels of pro-inflammatory Th1/Th17 cytokines in Tanzanian AD patients compared to Swiss AD patients.[5] Besides the divergence between the immune signatures, environmental exposures which can translate to sensitizations/allergies considerably differ among AD patients depending on their origin and environment. We have read with great interest the study of Lunjani et al.[1] in which they investigated the impact of diverse environmental and socioeconomic factors on atopic dermatitis (AD) immune endotypes in children living in South Africa. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.